CStone Pharmaceuticals (HKG:2616) said the first patient was successfully dosed in the global multicenter Phase I clinical trial of its independently developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, without infusion reactions or other adverse events, according to a Tuesday filing with the Hong Kong Stock Exchange.
CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4 to boost the immune response against tumors. It is designed to reinvigorate exhausted immune cells while neutralizing VEGF, making it a potential breakthrough for various cancers, including lung, liver, and ovarian cancer, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。